TP53の喪失は,結腸直腸がんにおける治療的脆弱性を生み出します
Yunhua Liu1, Xinna Zhang2, Cecil Han1
1Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Nature
|April 23, 2015
まとめ
TP53のゲノム削除は,RNAポリメラーゼIIにとって重要な遺伝子であるPOLR2Aをしばしば無効化する. POLR2Aを抑制すると,TP53の損失を伴う癌細胞を選択的に標的とし,一般的なヒトがんに対する新しい治療戦略を提供します.
科学分野:
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
- 遺伝学 遺伝学とは
背景:
- TP53は腫瘍抑制遺伝子であり,ヒトのがんでは頻繁に無活性化されます.
- p53の機能を回復することは,がん治療の目標ですが,複雑なシグナル伝達経路が進行を妨げています.
- TP53のゲノム削除は,隣接する重要な遺伝子の喪失とともに起こり得る.
研究 の 目的:
- TP53と共同で削除された遺伝子を特定し,その治療の可能性を探求する.
- TP53 欠損による癌におけるPOLR2Aの役割を調査する.
- 標的がん療法としてα-アマニチンとその抗体-薬物結合体を評価する.
主な方法:
- ガンゲノムアトラス (TCGA) とがん細胞系百科事典 (CCLE) のデータベースの分析.
- 結腸直腸がんにおけるPOLR2Aの遺伝子発現と複製数の分析.
- α-アマニチン,小干渉RNA,および抗体-薬物結合剤を用いたインビトロおよびインビボ研究.
主要な成果:
- POLR2AはしばしばTP53と共に共削除され,その発現は遺伝子コピー番号と相関する.
- POLR2Aの抑制は,半導体TP53喪失による結腸直腸がん細胞の増殖と生存を選択的に抑制する.
- α-アマニチン結合抗体-薬剤結合体は,高効能と低毒性を臨床前モデルで示した.
結論:
- POLR2Aをターゲットにすることは,TP53の欠失を伴うがんに対する新しい治療戦略です.
- α-amanitinの抗体-薬物結合体は,毒性の制限を克服するための有望なアプローチを提供します.
- このアプローチは,一般的なゲノム変異を持つヒトの癌の治療に潜在力を秘めています.
関連する概念動画
Abnormal Proliferation
5.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Loss of Tumor Suppressor Gene Functions
6.4K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
6.4K
Loss of Tumor Suppressor Gene Functions
2.1K
2.1K
Cancer-Critical Genes II: Tumor Suppressor Genes
10.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.4K
Cancer-Critical Genes II: Tumor Suppressor Genes
3.1K
3.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
70
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
70


